A trial looking at rucaparib for prostate cancer that has spread (TRITON3)
Cancer type:
Status:
Phase:
This trial compared a drug called rucaparib with for prostate cancer.
It was for men with:
- prostate cancer that had spread and got worse despite having hormone treatment. This is called metastatic castration resistant prostate cancer (mCRPC).
- certain gene changes (
mutations ) in the prostate cancer cells
The trial was open for people to join between 2017 and 2022. The team published the results in 2023.
More about this trial
Doctors often treat metastatic prostate cancer with hormone therapy and chemotherapy. But sometimes the cancer starts to grow again.
Doctors were looking at treatments to help people in this situation. In this trial they looked at a drug called rucaparib. It is a type of known as a PARP inhibitor. PARP is a protein (enzyme) found in our cells. It helps damaged cells to repair themselves.
As a cancer treatment, PARP inhibitors stop the PARP from doing its repair work in cancer cells and the cell dies.
The researchers knew that PARP inhibitors might help men whose prostate cancer cells have gene changes (mutations) including:
BRCA1 BRCA2 - ATM
In this trial, 2 out of every 3 people had rucaparib. And 1 out 3 every people had standard treatment. The standard treatments were:
- abiraterone – a hormone treatment
- enzalutamide – a hormone treatment
- docetaxel – a chemotherapy drug
The main aims of this phase 3 trial were to:
- see how well rucaparib works compared to standard treatment
- learn more about the side effects
- see how treatment affects
quality of life
Summary of results
4,855 people were considered for the trial. Only men who had one of the following genes changes could take part:
BRCA1 BRCA2 - ATM
To find this out the team looked at tissue samples, blood samples or both. They found that this applied to just under one in ten people (8%). This was 405 people out of 4,855.
A total of 405 men were put into a treatment group at random:
- 270 had rucaparib
- 135 had standard treatment
The doctor decided which treatment would work best for those having standard treatment.
In the rucaparib group:
- 201 people had the BRCA gene change
- 69 people had the ATM gene change
In the standard treatment group:
- 101 people had the BRCA gene change
- 34 people had the ATM gene change
The team looked at how long before the cancer started to grow again. At 5 years this was:
- 10.2 months in the rucaparib group
- 6.4 months in the standard treatment group
The team also looked at how long before the cancer started to grow again in those who had a BRCA gene change. At 5 years this was:
- 11.2 months in the rucaparib group
- 6.4 months in the standard treatment group
They also looked at how long before the cancer started to grow again in those who had the ATM gene change. This was about:
- 8.1 months in the rucaparib group
- 6.8 months in the standard treatment group
The results for these two groups do look different. But it is more likely that the difference is due to chance, and not differences in how well the treatments worked.
Quality of life
The team looked at how treatment affected quality of life. They didn’t find much of a difference between those who had rucaparib and those who had standard treatment.
Side effects
The team say the side effects were as expected.
Most people had at least 1 side effect from treatment. But some of these were mild or didn’t last long.
Some people had more severe side effects. This was:
- 161 out of 270 people (60%) in the rucaparib group
- 69 out of 130 people (53%) in the standard treatment group
The more severe side effects of rucaparib included:
- tiredness (fatigue)
- a drop in the number of blood cells causing an increased risk of infection and tiredness or breathlessness
The more severe side effects of standard treatment included:
- tiredness
- a drop in the number of white blood cells called
neutrophils causing an increased risk of infection
Conclusion
The trial team concluded that rucaparib increased the length of time before the cancer started to grow again. This was for men:
- who had metastatic prostate cancer and the BRCA gene change, and
- whose cancer had got worse despite hormone treatment
Rucaparib didn’t increase the length of time before the cancer started to grow again in those who had the ATM gene change.
The trial team say that testing the men’s cancer cells for these gene changes was useful. Even if they didn’t have the gene changes necessary to take part in this trial. It may have showed they were suitable for other clinical trials or . It also highlighted if someone may have had a family history of cancer.
More detailed information
There is more information about this research in the reference below.
Please note, the information we link to here is not in plain English. It has been written for healthcare professionals and researchers.
Rucaparib or Physician’s Choice in Metastatic Prostate Cancer
K. Fizazi and others
New England Journal of Medicine, 2023 388: pages 719-732
Where this information comes from
We have based this summary on the information in the article above. This has been reviewed by independent specialists () and published in a medical journal. We have not analysed the data ourselves. As far as we are aware, the link we list above is active and the article is free and available to view.
Recruitment start:
Recruitment end:
How to join a clinical trial
Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.
Chief Investigator
Dr Elias Pintus
Supported by
Clovis Oncology, Inc
If you have questions about the trial please contact our cancer information nurses
Freephone 0808 800 4040